Abstract
Objective: To evaluate the impact of cyclical low-dose micronised medroxyprogesterone (5 mg/day for the last 12 days of each 28-day cycle) in combination with 17-β estradiol (2 mg/day continuously) on lipid profiles in postmenopausal women treated for 12 months.
Design and Setting: Open, noncomparative, prospective study carried out in general practice.
Patients and Results: 98 female patients were enrolled; seven failed to meet entry criteria, 20 withdrew after developing adverse events, three were lost to follow up and one withdrew for personal reasons; 67 (67.3%) completed 12 months’ treatment. Levels of total cholesterol (6.42 mmol/L at baseline) fell 8.4% (p = 0.0001) after 12 months’ treatment, while total triglycerides (1.39 mmol/L at baseline) increased by 12.2% (p = 0.007), low density lipoprotein cholesterol (4.27 mmol/L at baseline) fell 18.3% (p = 0.0001) and high density lipoprotein (HDL) cholesterol (1.59 mmol/L at baseline) increased by 6.9% (p = 0.0001). The most frequently reported adverse events were menorrhagia, breast tenderness, cervical polyps or cysts, bloating, fatigue or lethargy, influenza or influenza-like syndrome, back pain and headaches.
Conclusions: Treatment with oral micronised 17-β estradiol 2 mg/day continuously and medroxyprogesterone 5 mg/day for 12 days of each 28-day cycle lead to changes in lipid profiles in postmenopausal women that had favourable implications for the risk of development of coronary heart disease. The 17-β estradiol-induced increase in the level of HDL cholesterol was maintained during combination with low-dose cyclical medroxyprogesterone for 12 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Heart Association, Dallas, Texas. Heart and stroke facts 1992
US Department of Health and Human Services. National Center for Health Statistics. US mortality tapes, 1968 to 1983. Washington DC: US Department of Health and Human Service, 1984
Castelli WP, Anderson KM. A population at risk 1986. Am J Med 1986; 80: 23–32
Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation 1987; 75(6): 1102–9
Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991; 325(11): 756–62
Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861–7
Penotti M, Farina M, Castiglioni E, et al. Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: a randomized crossover study. Am J Obstet Gynecol 1996; 175 (3 Pt 1): 606–11
Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91(7): 1952–8
Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28(10): 2077–80
Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20(4): 470–5
Lie RF, Schmitz JM, Pierre KJ, et al. Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum. Clin Chem 1976; 22(10): 1627–30
Yancey MK, Hannan Jr CJ, Plymate SR, et al. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990; 54(5): 778–82
Haarbo J, Hassager C, Jensen SB, et al. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives. Am J Med 1991; 90(5): 584–9
Kim CJ, Min YK, Ryu WS, et al. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: influence of various progestogens and duration of therapy. Arch Intern Med 1996; 156(15): 1693–700
Haines CJ, Chung TKH, Masarei JRL, et al. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis 1996; 119(2): 215–22
Writing Group for the PEPI. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3): 199–208
Vejtorp M, Christensen MS, Vejtorp L, et al. Serum lipoprotein changes in climacteric women induced by sequential therapy with natural estrogens and medroxy-progesterone acetate or norgestrel. Acta Obstet Gynecol Scand 1986; 65(5): 391–5
Lemay A, Dodin S, Cedrin I, et al. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate. Clin Endocrinol (Oxf) 1995; 42(4): 341–51
Miller VT, Muesing RA, LaRosa JC, et al. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol 1994; 83(2): 173–9
Wolfe BM, Huff MW Effects of continuous low-dosage hormonal replacement therapy on lipoprotein metabolism in postmenopausal women [Published erratum appears in Metabolism 1995; Jul 44 (7): 963]. Metabolism 1995; 44(3): 410–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harrison, R.F., Magill, P. & Kilminster, S.G. Impact of a New Formulation of Low-Dose Micronised Medroxyprogesterone and 17-β Estradiol on Lipid Profiles in Menopausal Women. Clin. Drug Investig. 16, 93–99 (1998). https://doi.org/10.2165/00044011-199816020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199816020-00001